Bullet Blog #4: Fast Facts About Cisplatin

May 9, 2024

  • First described by the Italian chemist Michele Peyrone in 1845, cisplatin is an alkylating agent that contains the metal platinum.
  • Its full name is cis-diamminedichloroplatinum (II).
  • Cisplatin is used to treat head and neck cancer as well as testicular, ovarian, bladder, esophagus, stomach, and lung cancers.
  • Its major side effects are nausea and vomiting, electrolyte abnormalities, bone marrow suppression, and damage to the kidneys, ears, eyes, and liver.
  • Cisplatin is not gendered; the prefix “cis-” comes from the Latin meaning “on this side,” as opposed to “trans-” which means “on the other side of” since both chlorines in cisplatin are located on the same side, as shown below.

  • In the KEVLARx clinical trial, patients are randomized to receive cisplatin and intensity modulated radiotherapy (IMRT) with or without lead EpicentRx small molecule, RRx-001 (nibrozetone).
  • The main endpoint in KEVLARx is the incidence of severe oral mucositis, which, hopefully, RRx-001 (nibrozetone) prevents or reduces.